

## **CV Inger Brattne**

Inger Brattne is currently an independent consultant, after having retired from her position at Pfizer, a global research based pharmaceutical company, in August 2018. At Pfizer, she was Cluster Legal Lead Southern Europe & Australia/NZ and Legal Lead Rare Diseases International Developed Markets as well as Senior Legal Director, Pfizer Health, Sweden. Her previous positions include that of Legal Lead for Pfizer International Operations & Strategy and Legal Lead for the Mid-Size Markets 1 in Europe and Legal Director Pfizer Sweden.

Inger Brattne joined Pfizer as Associate General Counsel following the merger with Pharmacia in 2003. Prior to that, she was legal counsel at Akzo Nobel, following a corresponding position at Astra (now Astra Zeneca). Before joining the private sector, Inger Brattne was hovrättsfiskal at the Svea Appellate Court, Stockholm. Inger Brattne received her law degree in 1979 from the University of Lund, Sweden, following studies in political science at Colorado College, Colorado. After her law degree, she performed research in international intellectual property law at the Max Planck Institute for Intellectual Property Law, Munich, and at the London School of Economics, London.

Inger Brattne has held various corporate and other boardpositions within and outside Pfizer. She is the former president of the Swedish Company Lawyers' Association. As a founder and executive director, she has also worked extensively on mentorship and diversity issues in various organizations, including in the Swedish Company Lawyers Association and Pfizer's ExPAND and WOC programs. For many years, she was also the chief editor of newsPfLAsh, a legal newsletter for in-house counsels in Europe.

Inger Brattne is currently on the board of the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) and is a member of the Swedish Anti-Corruption Institute's Ethics Committee.

\*\*\*